Fate Therapeutics sets up $100 million stock sale program with Leerink Partners

Fate Therapeutics, Inc. filed a prospectus supplement dated November 5, 2026 for an at-the-market stock offering program with Leerink Partners LLC, under which the company may offer and sell shares of common stock having an aggregate offering price of up to $100,000,000 from time to time through Leerink Partners, acting as sales agent.¹ Leerink Partners is not obligated to sell a set number of shares, but will work to sell stock under terms both parties agree to, using its standard sales practices. Leerink Partners will be entitled to compensation under the terms of the sales agreement at a commission rate of up to 3.0% of the gross proceeds of any shares of common stock sold under the sales agreement.¹ The company's common stock trades on The Nasdaq Global Market under the symbol "FATE," and on November 4, 2026, the last reported sale price was $2.09 per share.¹

The filing notes that in connection with entering into the sales agreement with Leerink Partners LLC, the company terminated its prior sales agreement with Jefferies LLC.¹ Under that earlier Jefferies program, during the three months ended September 30, 2026, Fate sold 2,801,602 shares of common stock for gross proceeds of $8.0 million.¹

On pipeline progress, Fate said in August 2026 it initiated RECLAIM-LN, its Phase 2 clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis, which the company believes may potentially support registration of FT819.¹ FT819 holds RMAT designation from the FDA for moderate to severe SLE including lupus nephritis, and the FT819-201 study was accepted in May 2026 into the agency's pilot program for chemistry, manufacturing, and controls review, titled the "Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program."

As of September 30, 2026, the company reported cash, cash equivalents and short-term investments of $139.1 million.¹